Participated · Equity · Nov 2021

Shoreline Biosciences is developing intelligently designed, off-the-shelf induced pluripotent stem cell (iPSC)-derived NK and macrophage cellular immunotherapies. The company focuses on standardized, targeted cell products including next-generation, more persistent iPSC-derived NK cells and macrophage-cell therapies. Shoreline is advancing proprietary iPSC differentiation methods, genetic reprogramming of disease-relevant pathways, and plans to create NK-specific CARs, switchable CAR-NK engagers, and macrophage-specific CARs. It targets both hematologic malignancies and solid tumors and has established strategic partnerships with Kite (a Gilead Company) and BeiGene. Shoreline also reports contract development and manufacturing organization (CDMO) partnerships to support manufacturing. The company is headquartered in San Diego, CA and is well-capitalized to continue pipeline advancement. Shoreline Biosciences is developing intelligently designed allogeneic, off-the-shelf natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC). The company focuses on standardized and targeted NK- and macrophage-based cell therapies for cancer and other serious diseases. It plans to use new funding to accelerate advancement of its proprietary iPSC platform and next-generation NK and macrophage cell therapy programs. Research efforts supported by the financing include work to create potent and persistent NK cell-specific chimeric antigen receptors (CARs), switchable CAR-NK cell engagers, and macrophage-specific CARs. Shoreline has entered a strategic relationship with the Advanced Cell Therapy Laboratory of UC San Diego to secure GMP manufacturing of its cell therapy products. The company was co-founded by Dan Kaufman, M.D., Ph.D., along with Steven Holtzman, William Sandborn, M.D., and Kleanthis G. Xanthopoulos, Ph.D.

Participated · Equity · Apr 2021

CeQur commercializes simple-to-use, wearable insulin-delivery devices designed to replace multiple daily injections, with CeQur Simplicity as its mealtime insulin patch offering. The company reports clinical evidence showing significantly improved A1C and time-in-range outcomes and cites studies and presentations supporting patient adherence. Adoption is expanding across primary care and endocrinology practices; the company says better than 85% of claims are covered as a pharmacy benefit with an average copay of less than $45 per month. Nearly 90% of patients reported better adherence with CeQur Simplicity versus multiple daily injections, according to cited patient-experience data. CeQur has new FDA clearances and an advancing pipeline that includes extended 7-day wear and 1-unit and 2-unit patch options. The company announced a $100 million Series E to fund commercial expansion, including growth of its field sales organization.

Participated · Series C · Nov 2020

Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for hematologic disorders by targeting epigenetic enzymes, principally LSD1. Its lead candidate, bomedemstat (IMG-7289), is an orally available small-molecule LSD1 inhibitor being evaluated in Phase 2b trials for myelofibrosis and essential thrombocythemia and is also being studied in other myeloid malignancy trials. The FDA has granted bomedemstat Fast Track and Orphan Drug Designations for myelofibrosis and essential thrombocythemia, and the EMA has given PRIME designation for myelofibrosis. Imago will use the proceeds from the financing to complete a Phase 3 study of bomedemstat for myeloproliferative neoplasms. The company is based in South San Francisco, California. Imago BioSciences is a clinical-stage, venture-backed pharmaceutical company focused on proliferative diseases of the bone marrow and immune modulation. Its lead program is IMG-7289, a small molecule LSD1 (KDM1A) inhibitor with demonstrated anti-tumor efficacy in non-clinical models and activity in combination with other agents. Imago completed a Phase 1/2a study of IMG-7289 in late 2018 and has initiated a global Phase 2b study in patients with myelofibrosis; additional indications are planned. The company intends to advance research and clinical development programs for myelofibrosis and other myeloid neoplasms. Imago is based in California and will use proceeds from its recent financing to fund these clinical programs. Imago BioSciences is a San Francisco–based clinical development company focused on therapeutics that alter gene expression patterns. It is dedicated to orphan diseases involving genetic alterations that disturb normal gene expression, and to conditions where modifying gene expression could have a therapeutic effect. The company is led by CEO Hugh Young Rienhoff, M.D. Proceeds from the recent financing will be used to advance its research and clinical development programs for these therapeutics. Imago raised $26.5M in a Series A to fund those programs. The round included participation from strategic life-science investors to support its clinical efforts.

Participated · Convertible Note · Jun 2018

Stealth BioTherapeutics focuses on developing therapies that directly address mitochondrial bioenergetic deficits across rare and age-related diseases. The company’s development portfolio includes elamipretide programs in Barth syndrome, polymerase gamma–related mitochondrial disease and dry age-related macular degeneration, a next-generation clinical candidate bevemipretide for ophthalmic and neurological indications, and preclinical assets SBT-255 and SBT-589 for rare mitochondrial disorders. Its parent, Mighty Therapeutics, achieved FDA approval in September 2025 for the first commercial therapy for Barth syndrome and the first FDA-approved therapy to directly target mitochondria, generating revenue from its lead commercial product. The company plans to use newly secured capital to accelerate commercial launch activities and advance late-stage and pipeline development programs. Financially, current cash, cash equivalents and product revenues are expected to extend runway into 2028, with additional financing drawdowns projected to support cash flow positivity in early 2029.